|The CD45.1 n/a (Catalog #MBS532090) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The CD45.1 antibody (Allophycocyanin-CY7) reacts with Murine and may cross-react with other species as described in the data sheet. MyBioSource\'s CD45.1 can be used in a range of immunoassay formats including, but not limited to, Flow Cytometry (FC/FACS), Immunohistochemistry (IHC). Researchers should empirically determine the suitability of the CD45.1 n/a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Mouse monoclonal CD45.1 antibody (Allophycocyanin-CY7).
Biological Significance: CD45 exists in multiple forms, such as the restricted variants and as allelic forms CD45.1/Ly5.1 and CD45.2/Ly5.2. The former arises as a result of alternative splicing of different exons. The specificity of antibodies to CD45.1 and CD45.2 has been exploited in studies in which resolution of donor and recipient cells is essential, such as in gene therapy or bone marrow transplantation. Biohazard Information: This product contains sodium azide as preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling this product.
Immunogen: CD45.1 (Allophycocyanin-CY7) antibody was raised in mouse using CD45.1 as the immunogen. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing CD45.1 are readily searchable from our website. Different antibodies against the same target such as CD45.1 may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.